{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:09Z","timestamp":1786119369993,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess the accuracy of\n                      <jats:sup>18<\/jats:sup>\n                      F choline PET\/magnetic resonance (MR) when compared with the reference standard MRI-guided template mapping (TPM) biopsies for evaluation of biochemical relapse of prostate cancer in patients with clinically significant and insignificant disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      A total of 26 prostate lobes in 13 patients with rise in prostate-specific antigen (PSA), age range 56\u201379; median 66 years, who had\n                      <jats:sup>18<\/jats:sup>\n                      F choline PET\/MR and underwent TPM. Whole body PET\/MR images were correlated with maximum cancer core length (MCCL) and total cancer core length (TCCL) obtained via TPM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the patients was 66 years (median: 66, range: 56\u201379 years), and the mean PSA level was 5.17 ng\/ml (median: 4.40 ng\/ml, range: 1.0\u201311.1 ng\/ml; Roche Modular method). The mean maximum standard uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) was 3.18 (median: 2.3, range: 0.6\u201312.3). The mean MCCL was 1.5 mm (range: 1\u20139 mm), mean TCCL was 3.1 mm (range: 1\u201328 mm). We evaluated the correlation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value) between MCCL, TCCL, and SUV\n                      <jats:sub>max<\/jats:sub>\n                      on\n                      <jats:sup>18<\/jats:sup>\n                      F choline PET\/MR with univariate analysis.\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value for MCCL was 0.078 and for TCCL 0.093. Overall, the sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve were 77, 70, 58, 85, and 0.621 (95% confidence interval: 2.16\u20134.19).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F choline PET\/MR allows detection of clinically significant and insignificant prostate cancer. Multiple previous treatments can give false positive results. False negative results with\n                      <jats:sup>18<\/jats:sup>\n                      F choline PET\/MR can be because of very small volume (\u22642 mm) disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002158","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:00:06Z","timestamp":1777363206000},"page":"994-1006","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["18F choline PET\/MR to assess clinically significant disease in prostate cancer: Correlation with maximum and total cancer core length obtained via template mapping biopsies"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-1299","authenticated-orcid":false,"given":"Athar","family":"Haroon","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, Barts Health NHS Trust, St Bartholomew\u2019s Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Almuhaideb","sequence":"additional","affiliation":[{"name":"Radiology Department, Nuclear Medicine Section, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sola","family":"Adeleke","sequence":"additional","affiliation":[{"name":"NIHR Academic Clinical Fellow in Clinical Oncology, King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura May","family":"Davis","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Endozo","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayjanah","family":"Allie","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Afaq","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University College London Hospital, London, UK"},{"name":"Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Mustafa Shah","family":"Syed","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Nuclear Medicine, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleen","family":"Ghafoor","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland\u2002and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"R1-20260708","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"},{"key":"R2-20260708","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.14151","article-title":"Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.","volume":"122","author":"Barnett","year":"2018","journal-title":"BJU Int"},{"key":"R3-20260708","doi-asserted-by":"crossref","first-page":"61","DOI":"10.6004\/jnccn.2015.0009","article-title":"Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.","volume":"13","author":"Aizer","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20260708","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.acra.2015.02.006","article-title":"Prostate MRI can reduce overdiagnosis and overtreatment of prostate cancer.","volume":"22","author":"Rosenkrantz","year":"2015","journal-title":"Acad Radiol"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"W92","DOI":"10.2214\/AJR.16.16876","article-title":"The learning curve in prostate MRI interpretation: self-directed learning versus continual reader feedback.","volume":"208","author":"Rosenkrantz","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"R6-20260708","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"45.e17","DOI":"10.1016\/j.urolonc.2013.06.007","article-title":"The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level \u2013 can it rule out clinically significant prostate cancer?","volume":"32","author":"Abd-Alazeez","year":"2014","journal-title":"Urol Oncol"},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1148\/radiol.2015142818","article-title":"Prostate cancer: interobserver agreement and accuracy with the revised Prostate Imaging Reporting and Data System at multiparametric MR imaging.","volume":"277","author":"Muller","year":"2015","journal-title":"Radiology"},{"key":"R9-20260708","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1148\/radiol.2018172619","article-title":"Impact of clinical history on maximum PI-RADS version 2 score: a six-reader 120-case sham history retrospective evaluation.","volume":"288","author":"Shankar","year":"2018","journal-title":"Radiology"},{"key":"R10-20260708","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1007\/s00330-017-4843-7","article-title":"A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.","volume":"27","author":"Zhang","year":"2017","journal-title":"Eur Radiol"},{"key":"R11-20260708","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2214\/AJR.15.15679","article-title":"(18)F-FECH PET\/CT to assess clinically significant disease in prostate cancer: correlation with maximum and total cancer core length obtained via MRI-guided template mapping biopsies.","volume":"207","author":"Haroon","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"R12-20260708","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.juro.2011.03.147","article-title":"Characterizing clinically significant prostate cancer using template prostate mapping biopsy.","volume":"186","author":"Ahmed","year":"2011","journal-title":"J Urol"},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1200\/JCO.2008.20.3497","article-title":"Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.","volume":"27","author":"Onik","year":"2009","journal-title":"J Clin Oncol"},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.juro.2007.03.003","article-title":"Guideline for the management of clinically localized prostate cancer: 2007 update.","volume":"177","author":"Thompson","year":"2007","journal-title":"J Urol"},{"key":"R15-20260708","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2967\/jnumed.119.225789","article-title":"18F-choline PET\/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies.","volume":"61","author":"Davenport","year":"2020","journal-title":"J Nucl Med"},{"key":"R16-20260708","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1148\/radiol.2463062080","article-title":"MR imaging of prostate after treatment with high-intensity focused ultrasound.","volume":"246","author":"Kirkham","year":"2008","journal-title":"Radiology"},{"key":"R17-20260708","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1742-4682-7-23","article-title":"Transperineal prostate biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies.","volume":"7","author":"Kepner","year":"2010","journal-title":"Theor Biol Med Model"},{"key":"R18-20260708","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/00000478-199909000-00004","article-title":"Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues.","volume":"23","author":"Gaudin","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"R19-20260708","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2559.1997.d01-621.x","article-title":"Effects of radiation on the normal prostate gland.","volume":"30","author":"Sheaff","year":"1997","journal-title":"Histopathology"},{"key":"R20-20260708","first-page":"187","article-title":"Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.","volume":"43","author":"Hara","year":"2002","journal-title":"J Nucl Med"},{"key":"R21-20260708","doi-asserted-by":"crossref","first-page":"e70274","DOI":"10.1002\/mp.70274","article-title":"PSMA PET\/MRI-based Swin Transformer architecture for Gleason score prediction in prostate cancer.","volume":"53","author":"Yang","year":"2026","journal-title":"Med Phys"},{"key":"R22-20260708","first-page":"224","article-title":"PSMA-directed PET\/MRI enables noninvasive diagnosis and prognosis in patients with increased PSA levels: results from the prospective randomized RAPID trial.","volume":"67","author":"Hartenbach","year":"2026","journal-title":"J Nucl Med"},{"key":"R23-20260708","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/tomography8050205","article-title":"Prostate cancer biochemical recurrence resulted negative on [68Ga]Ga-PSMA-11 but positive on [18F]fluoromethylcholine PET\/CT.","volume":"8","author":"Laudicella","year":"2022","journal-title":"Tomography"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:22:57Z","timestamp":1786040577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002158","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2026-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}